Metropolis Healthcare

1,853.30
-6.10
(-0.33%)
Market Cap
9,600.44 Cr
EPS
28.29
PE Ratio
66.39
Dividend Yield
0.00 %
52 Week High
2,318.30
52 Week Low
1,315.00
PB Ratio
7.23
Debt to Equity
0.22
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+68.75 %
+68.75 %
Hold
Hold+6.25 %
+6.25 %
Sell
Sell+25.00 %
+25.00 %

Company News

View All News
Caret
positive
Metropolis Healthcare has reported significant revenue growth for Q1. The company's overall revenue increased by approximately 23% year-over-year. Notably, the specialty revenues segment showed an even stronger performance, growing by approximately 35%+ compared to the same period last year.
positive
Metropolis Healthcare: Q1 Revenue Surges 23% YoY3 days ago
Metropolis Healthcare reported a 23% year-on-year revenue growth for Q1 FY26. Core Diagnostics moved to positive margins. Specialty revenues grew 35% YoY. Excluding acquisitions, revenues increased 13% YoY. B2C revenues up 15%. TruHealth Wellness and Specialty segments grew 20% and 15% respectively. EBITDA improved QoQ. Company remains debt-free.
positive
Metropolis Healthcare has reported a significant increase in revenue for the first quarter. The company's revenue grew by approximately 23% compared to the same quarter in the previous year. Notably, specialty revenues showed an even more substantial increase, rising by over 35% year-over-year.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
2,875.00
#1 24,085.46
48.92
#1 2,554.80
11.28
#1 492
81.24
53.16
1,001.00
10,278.98
72.14
681.39
20.11
152
3.56
65.15
1,853.30
#3 9,600.44
#8 66.39
#2 1,331.20
#10 4.59
#3 142
#10 -20.00
63.94
1,049.15
5,559.91
62.26
687.35
8.63
98
25.58
58.44
754.25
2,435.46
30.79
717.16
25.65
81
10.70
59.17
320.90
1,671.27
52.91
252.09
14.77
31
14.29
47.92
1,598.00
1,371.50
29.06
96.47
25.47
49
-9.09
53.43
280.20
891.33
#1 9.47
1,110.95
35.04
-197
-18.52
50.46
280.10
547.39
28.63
147.04
#1 248.07
18
#1 175.00
54.82
182.00
126.75
83.40
41.78
6.34
1
28.57
66.97
Forecast
Actual
Growth Rate
Revenue Growth
4.59 %
Net Income Growth
-10.39 %
Cash Flow Change
6.87 %
ROE
-19.21 %
ROCE
-13.10 %
EBITDA Margin (Avg.)
-8.13 %

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
530
553
752
1,004
1,530
1,502
1,555
1,867
Fixed Assets
207
213
296
343
1,059
1,121
1,177
857
Current Assets
300
305
397
609
393
303
316
346
Capital Work in Progress
0
6
3
0
6
20
0
0
Investments
102
33
14
10
16
15
55
48
Other Assets
221
301
439
651
450
347
323
0
Total Liabilities
530
553
752
1,004
1,530
1,502
1,555
1,867
Current Liabilities
91
125
170
204
302
265
246
294
Non Current Liabilities
11
8
58
92
341
246
210
238
Total Equity
429
420
525
708
888
991
1,099
1,331
Reserve & Surplus
405
409
513
696
876
978
1,086
1,321
Share Capital
10
10
10
10
10
10
10
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
4
14
-1
18
8
56
279
-321
3
-6
Investing Activities
-56
96
-86
1
36
-104
63
-736
48
-89
Operating Activities
70
91
102
104
90
215
249
253
247
264
Financing Activities
-10
-174
-17
-87
-118
-55
-33
163
-292
-181

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
50.38 %
50.37 %
50.33 %
49.50 %
49.79 %
49.79 %
49.76 %
49.76 %
49.75 %
49.75 %
49.74 %
49.74 %
49.67 %
49.62 %
49.43 %
49.40 %
48.90 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
24.29 %
0.00 %
18.90 %
18.25 %
18.56 %
16.73 %
15.29 %
DIIs
15.34 %
14.22 %
11.77 %
10.63 %
15.32 %
13.85 %
11.88 %
13.30 %
13.64 %
14.47 %
16.86 %
20.28 %
24.86 %
27.43 %
28.02 %
30.00 %
30.30 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
3.95 %
3.98 %
4.24 %
6.50 %
9.14 %
9.26 %
9.45 %
9.73 %
8.53 %
8.15 %
7.78 %
6.63 %
5.24 %
4.07 %
3.54 %
3.34 %
3.84 %
Others
30.33 %
31.43 %
33.66 %
33.37 %
25.75 %
27.10 %
28.91 %
27.21 %
28.08 %
27.62 %
1.32 %
23.35 %
1.33 %
0.63 %
0.45 %
0.53 %
1.68 %
No of Share Holders
30,679
33,527
43,552
64,168
79,895
86,404
90,090
91,452
84,269
89,692
86,249
79,878
68,283
58,108
51,852
48,572
49,293

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 13.26 8 8 8 8 4 0.00
Dividend Yield (%) 0.00 0.00 0.00 1.03 0.36 0.39 0.67 0.46 0.26 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 1,701.10 1,701.85
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2025 1,791.25 1,737.90
08 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Nov 2024 2,139.95 2,115.45
21 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Aug 2024 2,118.90 2,095.85
17 Nov 2023 DIVIDEND Dividend
₹ 4.00 /share
17 Nov 2023 1,472.25 1,616.00
23 Feb 2023 DIVIDEND Dividend
₹ 8.00 /share
23 Feb 2023 1,286.75 1,336.85
22 Feb 2022 DIVIDEND Dividend
₹ 8.00 /share
21 Feb 2022 2,421.65 2,031.10
19 Feb 2021 DIVIDEND Dividend
₹ 8.00 /share
17 Feb 2021 2,143.40 1,970.65

Announcements

Business Update For Q1FY263 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 days ago
Closure of Trading Window7 days ago
Announcement under Regulation 30 (LODR)-Change in ManagementJun 18, 2025
Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 18 2025Jun 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 16, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 03 2025Jun 02, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 24, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025May 13, 2025
Board Meeting Outcome for For The Meeting Held Today (May 13 2025)May 13, 2025
Board Meeting Outcome for For The Meeting Held Today (May 13 2025)May 13, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)May 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 05, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 07, 2025
Business Update For Q4FY25Apr 05, 2025
Closure of Trading WindowMar 31, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 22, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 17, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 17, 2025

Technical Indicators

RSI(14)
Neutral
73.23
ATR(14)
Volatile
45.53
STOCH(9,6)
Neutral
79.51
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
12.03
ADX(14)
Strong Trend
26.56
UO(9)
Bearish
67.12
ROC(12)
Uptrend And Accelerating
10.47
WillR(14)
Overbought
-7.51

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Focused Fund Direct-Growth
0.00%
-1700000
-1.46%
-1.56%
HDFC Flexi Cap Direct Plan-Growth
0.00%
-1625000
-0.36%
-0.37%
Nippon India Small Cap Fund Direct- Growth
0.00%
-1145336
-0.31%
-0.34%
Kotak Small Cap Fund Direct-Growth
0.00%
-1085864
-1.05%
-1.16%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-800000
-0.82%
-0.84%
Franklin India Smaller Companies Fund Direct-Growth
0.00%
-790459
-0.98%
-1.07%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.00%
-700000
-0.52%
-0.53%
HDFC Hybrid Equity Fund Direct Plan-Growth
0.00%
-612876
-0.42%
-0.44%
Canara Robeco Small Cap Fund Direct - Growth
0.00%
-582930
-0.79%
-0.86%
Tata Business Cycle Fund Direct - Growth
0.00%
-316156
-1.83%
-1.51%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-245782
-2.42%
-2.51%
Tata Focused Fund Direct - Growth
0.00%
-223255
-2.09%
-2.16%
Kotak Contra Fund Direct-Growth
0.00%
-223102
-0.88%
-0.93%
Kotak Balanced Advantage Fund Direct - Growth
0.00%
-218019
-0.21%
-0.22%
Sundaram Services Fund Direct - Growth
0.00%
-206251
-0.83%
-0.75%
Franklin India Opportunities Direct Fund-Growth
0.00%
-196502
-0.48%
-0.51%
Sundaram Multi Cap Fund Direct-Growth
0.00%
-174800
-1.06%
-1.09%
Sundaram Flexi Cap Fund Direct - Growth
0.00%
-150000
-1.23%
-1.27%
Tata India Pharma & Healthcare Fund Direct-Growth
0.00%
-136636
-1.86%
-1.90%
Sundaram Business Cycle Fund Direct - Growth
0.00%
-106286
-1.02%
-0.95%
JM Aggressive Hybrid Fund Direct-Growth
0.00%
-100000
-2.04%
-2.12%
Templeton India Value Fund Direct Plan-Growth
0.00%
-100000
-0.76%
-0.78%
Franklin India Equity Hybrid Fund Direct-Growth
0.00%
-100000
-0.77%
-0.41%
Sundaram ELSS Tax Saver Fund Direct
0.00%
-98000
-1.21%
-1.26%
Franklin India Balanced Advantage Fund Direct - Growth
0.00%
-95000
-0.60%
-0.33%

About Metropolis Healthcare

Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years, -7 days)
Chairperson NameAmeera Sushil Shah